What is alcoholic hepatitis?

What is Alcoholic Hepatitis?

Alcoholic hepatitis is a serious, acute inflammatory liver condition that develops in heavy drinkers, characterized by rapid onset of jaundice, elevated liver enzymes, and systemic inflammation, carrying a 40-50% mortality rate within 90 days without treatment and abstinence. 1

Clinical Definition and Diagnostic Criteria

Alcoholic hepatitis (AH) represents an acute decompensation of alcohol-associated liver disease occurring in patients with prolonged heavy alcohol consumption 1. The condition is defined by specific clinical and laboratory parameters:

Key Diagnostic Features:

• Onset of jaundice within 60-90 days of heavy alcohol consumption (>40-50 g/day for at least 6 months, typically years) 1, 2
• Serum bilirubin >3.0 mg/dL 1
• Serum AST 50-400 IU/L with AST/ALT ratio >1.5 (often >2) 1, 3
• Clinical presentation: malaise, anorexia, tender hepatomegaly, and features of systemic inflammatory response syndrome (SIRS) including fever, tachycardia, and leukocytosis 1

Histologic Features (when biopsy performed):

The pathology shows macrovesicular steatosis, hepatocyte ballooning degeneration, neutrophil infiltration, Mallory-Denk bodies, megamitochondria, and chicken-wire fibrosis 1. Importantly, the vast majority of patients with severe AH have underlying cirrhosis at diagnosis, though the acute presentation may suggest a purely acute process 1.

Disease Spectrum and Classification

The NIAAA Alcoholic Hepatitis Consortium classifies AH as 1, 2:

• Definite AH: Liver biopsy-confirmed diagnosis
• Probable AH: Clinical and laboratory features present without confounding factors
• Possible AH: Clinical features present with potential confounding problems

AH exists within the broader spectrum of alcohol-associated liver disease, which ranges from simple steatosis → alcoholic steatohepatitis → fibrosis → cirrhosis 3, 4, 5.

Pathophysiology and Risk Factors

AH is fundamentally an inflammatory condition driven by multiple mechanisms 1:

• Alcohol-induced hepatocyte damage and oxidative stress
• Gut-derived microbial components triggering immune activation
• Pro-inflammatory cytokine release (particularly TNF-α)
• Neutrophil and macrophage recruitment to the liver
• Progressive stellate cell activation leading to fibrosis

Established Risk Factors:

• Female sex (women develop AH at lower alcohol thresholds and shorter duration) 1
• Elevated body mass index 1
• Genetic factors: PNPLA3 G allele polymorphism 1
• Duration and quantity of alcohol: Typically >40 g/day for women, >50-60 g/day for men, for >6 months to years 1, 2

Clinical Severity and Prognosis

Severity Assessment Tools:

Multiple validated scoring systems predict mortality 1:

• Maddrey Discriminant Function (MDF) >32: Predicts high 28-day mortality (defines severe AH)
• MELD score >20: Predicts high 90-day mortality
• ABIC score category C: Predicts high 28- and 90-day mortality
• Glasgow Alcoholic Hepatitis Score ≥9: Predicts high 28-day mortality

Mortality Risk:

• Without treatment and continued drinking: 40-50% mortality within 90 days 1
• Severe AH (MDF >32): Historically >50% 28-day mortality, though improved supportive care has reduced this to ~17-35% in recent trials 1
• Long-term prognosis: Even with treatment, 1-year mortality approaches 56%, and 4-year mortality reaches 65% in those with underlying cirrhosis 1

Critical Clinical Complications

Patients with AH face multiple life-threatening complications 1:

• Infections: Impaired immune function (particularly neutrophil dysfunction) increases bacterial and fungal infection risk
• Acute kidney injury (AKI): Common and associated with significantly increased mortality 6
• Multiorgan failure (MOF) syndrome: Often triggered by infections developing after initial diagnosis
• SIRS: Presence on admission increases risk of MOF and predicts very poor outcomes 1

Important Clinical Pitfall:

The onset of jaundice in any patient with chronic liver disease, particularly alcoholic liver disease, is an ominous sign indicating decompensation 1. Despite the name suggesting an acute process, most patients already have cirrhosis at AH diagnosis, making this a critical point for aggressive intervention.

Distinguishing Features from Other Conditions

AH must be differentiated from 1:

• Nonalcoholic steatohepatitis (NASH): Distinction relies on alcohol consumption history (>40-50 g/day) and rapid jaundice onset
• Viral hepatitis: Exclude through serologic testing
• Drug-induced liver injury: Careful medication history
• Ischemic hepatitis: Clinical context and pattern of enzyme elevation

The AST/ALT ratio >1.5 is highly characteristic, with ratios <1.5 seen in <2% of biopsy-proven AH cases 2. AST levels typically remain <400 IU/L, distinguishing AH from acute viral or ischemic hepatitis where levels often exceed 1000 IU/L.

Contemporary Context

The burden of AH is increasing, particularly noted during the COVID-19 pandemic with rising alcohol consumption 7, 8. AH now competes with hepatitis C as a leading indication for liver transplantation in the United States 4. The disease carries significant stigma, and there is movement toward using "alcohol-associated" rather than "alcoholic" terminology to reduce this barrier to care 4.